Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Transplant nephrology
How do you distinguish TMA caused by CNI toxicity versus antibody mediated rejection in a kidney transplant patient?
Related Questions
Do you routinely use markers or tests other than serum creatinine when estimating GFR to determine if patients with liver failure, not on dialysis, meet criteria for a simultaneous liver-kidney transplant?
What is your approach to dose adjusting mycophenolate in a kidney transplant recipient who is transitioned from tacrolimus to cyclosporine?
Would you recommend routinely checking ANCA levels just prior to a planned kidney transplantation in patients with a history of ESKD secondary to ANCA-associated vasculitis?
Do you taper steroids more aggressively to decrease the risk of developing new-onset diabetes after transplantation in kidney transplant recipients who had pretransplant impaired fasting glucose?
What is your approach to waiting period for an ESKD patient getting a kidney transplant after just being treated for bacteremia?
When do you recommend genetic testing prior to kidney transplantation for a patient with ESKD secondary to FSGS?
How would you approach management of a patient with ESRD on the transplant list who is found to have high titer APS labs (ACL, B2GP1, LAC)?
How much proteinuria would warrant consideration of native kidney nephrectomies at the time of a kidney transplant?
How do you approach chronic active AMR concurrent with changes of CNI toxicity?
What is your approach to managing a kidney transplant patient who develops BK viremia after treatment for rejection?
